D
David Ulmert
Researcher at University of California, Los Angeles
Publications - 92
Citations - 4622
David Ulmert is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 31, co-authored 87 publications receiving 3943 citations. Previous affiliations of David Ulmert include Lund University & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
TL;DR: Testing for prostate-specific antigen (PSA) has profoundly affected the diagnosis and treatment of prostate cancer and has created controversy over whether the authors are now diagnosing and treating insignificant cancers.
Journal ArticleDOI
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.
Andrew J. Vickers,David Ulmert,David Ulmert,Daniel Sjöberg,Caroline J Bennette,Thomas Björk,Axel Gerdtsson,Jonas Manjer,Peter M. Nilsson,Anders Dahlin,Anders Bjartell,Peter T. Scardino,Hans Lilja +12 more
TL;DR: Measurement of PSA concentration in early midlife can identify a small group of men at increased risk of prostate cancer metastasis several decades later, and three lifetime PSA tests are probably sufficient for at least half of men.
Journal ArticleDOI
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study
Andrew J. Vickers,Angel M. Cronin,Thomas Björk,Jonas Manjer,Peter M. Nilsson,Anders Dahlin,Anders Bjartell,Peter T. Scardino,David Ulmert,Hans Lilja +9 more
TL;DR: Though men aged 60 with concentrations below the median (≤1 ng/ml) might harbour prostate cancer, it is unlikely to become life threatening and such men could be exempted from further screening, which should instead focus on men with higher concentrations.
Journal ArticleDOI
Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years
Hans Lilja,David Ulmert,Thomas Björk,Charlotte Becker,Angel M. Serio,Jan-Åke Nilsson,Per-Anders Abrahamsson,Andrew J. Vickers,Göran Berglund +8 more
TL;DR: A single PSA test at age 44 to 50 years predicts subsequent clinically diagnosed prostate cancer, which raises the possibility of risk stratification for prostate cancer screening programs.
Journal ArticleDOI
Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy
Ariel E. Marciscano,Ali Ghasemzadeh,Thomas R. Nirschl,Debebe Theodros,Christina M. Kochel,Brian Francica,Yuki Muroyama,Robert A. Anders,Andrew B. Sharabi,Esteban Velarde,Wendy Mao,Kunal R. Chaudhary,Matthew G. Chaimowitz,John Wong,Mark J. Selby,Kent B. Thudium,Alan J. Korman,David Ulmert,Daniel L.J. Thorek,Theodore L. DeWeese,Charles G. Drake +20 more
TL;DR: It is highlighted that irradiation of the DLN restrains adaptive immune responses through altered chemokine expression and CD8+ T-cell trafficking and has implications for combining radiotherapy and ICB, long-term survival, and induction of immunologic memory.